Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1210 plus pemetrexed and carboplatin vs pemetrexed and carboplatin in first-line EGFR/ALK wild-type non-squamous NSCLC
CTR20170322Phase 3Active
- Sponsor
- Hengrui Therapeutics
- Start
- Apr 2017
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of camrelizumab in Non-small cell lung cancer (NS-NSCLC), sponsored by Hengrui Therapeutics. Started Apr 2017; status: active.
02
Drugs
camrelizumab
03
Conditions
Non-small cell lung cancer (NS-NSCLC)
Beyond the preview
Go deeper on CTR20170322.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20170322.